Purpose: To evaluate the quality of 24- hour intraocular pressure (IOP) control between morning-and evening-dosed travoprost in primary open-angle glaucoma patients. Design: Prospective, crossover, double-masked compa...Purpose: To evaluate the quality of 24- hour intraocular pressure (IOP) control between morning-and evening-dosed travoprost in primary open-angle glaucoma patients. Design: Prospective, crossover, double-masked comparison. Methods: After a 6- week medicine-free period, 33 patients were randomized to receive travoprost dosed in the morning or evening. After 8 weeks of treatment, a 24- hour IOP curve was performed at 6 am, 10 am, 2 pm, 6 pm, 10 pm, and 2 am. Patients were then treated with the opposite dosing regimen for another 8 weeks, after which the 24- hour IOP curve was repeated. MainOutcome Measures: Twenty-four-hour IOP. Results: The untreated mean 24- hour IOP was 23.6± 2.0 mmHg. There were no differences for mean 24- hour IOP between the morning (17.5± 1.9mmHg)-and evening (17.3± 1.9 mmHg) dosings (P=0.7). At 10 am, the evening dosing provided a statistically lower IOP (17.2± 2.1 mmHg) than the morning dosing (19.1± 2.5mmHg) (P=0.02). Evening dosing demonstrated a statistically lower 24- hour fluctuation of IOP (3.2± 1.0 mmHg) than morning dosing (4.0± 1.5 mmHg) (P=0.01). Safety was similar, with conjunctival hyperemia being the most common adverse event (n=9 [27% for morning dosing] and n=11 [33% for evening dosing], P=0.6). Conclusions: This study suggests that both morning and evening dosings of travoprost provide effective 24- hour IOP reduction. However, the evening dosing of travoprost demonstrates slightly greater daytime efficacy, with a narrower range of 24- hour pressure.展开更多
文摘Purpose: To evaluate the quality of 24- hour intraocular pressure (IOP) control between morning-and evening-dosed travoprost in primary open-angle glaucoma patients. Design: Prospective, crossover, double-masked comparison. Methods: After a 6- week medicine-free period, 33 patients were randomized to receive travoprost dosed in the morning or evening. After 8 weeks of treatment, a 24- hour IOP curve was performed at 6 am, 10 am, 2 pm, 6 pm, 10 pm, and 2 am. Patients were then treated with the opposite dosing regimen for another 8 weeks, after which the 24- hour IOP curve was repeated. MainOutcome Measures: Twenty-four-hour IOP. Results: The untreated mean 24- hour IOP was 23.6± 2.0 mmHg. There were no differences for mean 24- hour IOP between the morning (17.5± 1.9mmHg)-and evening (17.3± 1.9 mmHg) dosings (P=0.7). At 10 am, the evening dosing provided a statistically lower IOP (17.2± 2.1 mmHg) than the morning dosing (19.1± 2.5mmHg) (P=0.02). Evening dosing demonstrated a statistically lower 24- hour fluctuation of IOP (3.2± 1.0 mmHg) than morning dosing (4.0± 1.5 mmHg) (P=0.01). Safety was similar, with conjunctival hyperemia being the most common adverse event (n=9 [27% for morning dosing] and n=11 [33% for evening dosing], P=0.6). Conclusions: This study suggests that both morning and evening dosings of travoprost provide effective 24- hour IOP reduction. However, the evening dosing of travoprost demonstrates slightly greater daytime efficacy, with a narrower range of 24- hour pressure.
